Black Diamond Therapeutics (BDTX) Operating Income: 2018-2021
Historic Operating Income for Black Diamond Therapeutics (BDTX) over the last 3 years, with Dec 2021 value amounting to -$26.1 million.
- Black Diamond Therapeutics' Operating Income fell 12.50% to -$26.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$115.3 million, marking a year-over-year decrease of 65.79%. This contributed to the annual value of -$126.9 million for FY2021, which is 82.37% down from last year.
- Per Black Diamond Therapeutics' latest filing, its Operating Income stood at -$26.1 million for Q4 2021, which was up 26.25% from -$35.4 million recorded in Q3 2021.
- In the past 5 years, Black Diamond Therapeutics' Operating Income registered a high of -$3.0 million during Q4 2018, and its lowest value of -$35.4 million during Q3 2021.
- In the last 3 years, Black Diamond Therapeutics' Operating Income had a median value of -$15.0 million in 2020 and averaged -$17.4 million.
- Data for Black Diamond Therapeutics' Operating Income shows a maximum YoY tumbled of 239.59% (in 2019) over the last 5 years.
- Black Diamond Therapeutics' Operating Income (Quarterly) stood at -$3.0 million in 2018, then slumped by 239.59% to -$10.3 million in 2019, then crashed by 124.12% to -$23.2 million in 2020, then fell by 12.50% to -$26.1 million in 2021.
- Its Operating Income was -$26.1 million in Q4 2021, compared to -$35.4 million in Q3 2021 and -$30.7 million in Q2 2021.